Collaboration

Strategic research partnerships bring together knowledge, expertise and technologies, allowing advancements in our understanding of diseases and therapeutics that would not be possible in isolation. Optibrium and PostEra integrate AI drug discovery solutions Optibrium and PostEra plan to integrate Optibrium’s StarDrop platform with PostEra’s Manifold software. StarDrop’s drug discovery software includes de novo compound design, […]

Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. The collaboration focuses on the development of two investigational antibody candidates, UCB6114 and UCB4594, by bringing together the oncology-focused translational research and clinical development capabilities of Cancer Research UK, and UCB’s antibody […]

African researchers are now able to access Collaborative Drug Discovery’s CDD Vault resource for neglected disease drug discovery collaborations.  Collaborative Drug Discovery (CDD), a scientific informatics company that provides data management and analysis solutions, is offering free subscriptions to CDD Vault for select academic teams of scientists in Africa who are developing new drugs to combat neglected […]

The Pistoia Alliance Pharma Innovation Council has been launched, bringing together 13 leaders from large global pharmaceutical companies.   The Council will explore common challenges at a grassroots level and seed ideas for new pre-competitive projects aligned with the Alliance’s strategic themes: Emerging Sciences and Technology, Improving the Efficiency and Effectiveness of R&D, and Empowering the […]

The Duke Clinical Research Institute (DCRI) and Protas, led by Oxford University clinical trialist Professor Sir Martin Landray, will collaborate to develop new approaches to large randomised clinical trials.  Through the collaboration, the partners hope to enable better evidence-based treatments for common conditions, such as heart and kidney disease, hypertension, diabetes, stroke and Covid-19, by […]

Cancer Research Horizons and Singapore’s Experimental Drug Development Centre (EDDC) have announced a five-year strategic partnership to accelerate the translation of cancer research into improved treatments for cancer patients.   The international alliance will focus on leveraging the complementary capabilities, platforms and technologies from both partners, to accelerate oncology pipeline assets across a range of developmental […]

The Tecan Group and Oxford Nanopore Technologies will collaborate to drive easier high throughput nanopore library preparation in an automated, hands-free fashion.   The aim of the partnership is a fully automated workflow for Oxford Nanopore’s Ligation Sequencing Kit XL V14 protocol (LSK114) with Tecan’s DreamPrep NGS solutions.  The LSK114 protocol allows for any fragment length […]

Under a new agreement, Destiny Pharma and Sebela Pharmaceuticals will co-develop NTCD-M3, Destiny’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence.  It is anticipated that Sebela will lead and finance the future clinical development and commercialisation activities of NTCD-M3 in North America.   Destiny will keep most rights for Europe and Rest of […]

Charles River Laboratories and Pioneering Medicines have entered a multi-programme agreement that gives Pioneering Medicines access to artificial intelligence (AI) model Logica.  Through the agreement, Pioneering Medicines will apply Logica across a portfolio of targets with the aim of creating optimised small molecules that will lead to novel therapies for unmet medical needs.  “We are […]

Indee Labs and GenScript have formed a research collaboration with the aim to develop a DNA knock-in kit for Hydropore to enable large transgene inserts above the 5kb limit for AAV.  As part of the collaboration, GenScript will provide a variety of single-strand and double-strand (ssDNA and dsDNA) constructs for direct DNA inserts, while the […]